A four-dimensional view of breast cancer treatment
Dr. Joe Gray, director of the Oregon Health & Science University Center for Spatial Systems Biomedicine, addressed a capacity crowd at the Environmental Molecular Sciences Laboratory Auditorium at Pacific Northwest National Laboratory on April 18 regarding his research involving a systems approach to breast cancer. Gray was at PNNL as part of the ongoing Frontiers in Biological Sciences Seminar series, which features academic, government, and industrial leaders who discuss novel ideas and scientific advances in biological sciences.
According to Gray, there is a need to identify a better group of drugs that will respond to metastatic breast cancer. Currently, early analysis can result in as much as a 98 percent survival rate, while survival rates for metastatic breast cancer hover near 25 percent and have remained unchanged for many years.
"Hundreds of compounds are approved or well along in the development pipeline," Gray said. "There is nearly $20 billion in annual investment. However, each drug has specificity, and the heterogeneity between tumors is different. We need to determine the recurrent features that are attackable and respond to therapies."
Gray, who until recently served as an Associate Laboratory Director for Biosciences at Lawrence Berkeley National Laboratory and professor at the University of California, Berkeley, explained how diverse support from a multi-member consortium, with membership spanning public government and academic institutions to the private sector, fuels the systemic research to match treatments to "omes," which he fully expects will involve future collaborations using EMSL's user capabilities as well as PNNL and EMSL staff.
Gray's discussion focused on two targeted therapiessubtype-specific and ErbB2, or erythroblastic leukemia viral oncogene homolog 2as well as his spatial systems approach of integrating data derived from multiple research areas to generate a higher-order understanding of cancers.
Beyond cataloging, Gray explained how understanding the manifestation of the 'omic time-dependent phenomenon is something that needs to be studied. What happens at receptors and within the microenvironment in metastatic cancer and how they influence responses will only become clearer as source information and models improve to account for composition and functional variations over time and space.
"To take the next steps in research, you have to understand more than the histopathology and genomics, you have to understand how these systems work in four dimensionsthree-dimensional space and time," he said.
Two well-organized international cancer genomics efforts are defining cancer subtypes.
The Cancer Genome Atlas is cataloguing genetic mutations responsible for cancer using high-throughput genome analysis techniques. Already, there are 500 breast cancers available. Data concerning the abnormalities composing these cancers are contributing to Gray's systemic matching of the "ome" and response. The well-characterized cancer cell lines are used to model molecular diversity of primary tumors. Gray's group has tested 100 therapeutic compounds in more than 50 breast cancer cell lines to identify molecular response predictors. Half of all compounds show subtype specificity.
"Using these 100 cell lines as a model of diversity of agents that target or drive genomic aberrations is proving effective," he said.
Gray's group also uses the University of California, Santa Cruz (UCSC) Cancer Genomics Browser that allows users to click and sort data to identify molecular features. Per Gray, It has the potential to pull together all the data in the world on cancer. Pathway Recognition Algorithm using Data Integration on Genomic Models, or PARADIGM, allows researchers to take multiple aspects of genomic data and calculate pathway activity, which is crucial in generating connections between molecular markers and outcome.
Gray used a basal breast cancer example to show how analyzing subtype-specific activated pathways can show drug interaction/responses and individual DNA changes within cancer cells. By analyzing cancer cell DNA, specific cell aspects can be targeted and killed. Ultimately, these efforts will allow researchers to take some integrated molecular data (such as the DNA damage network in breast cancer), test it in model systems, and move these into clinical trials with confidence that there will be responses.
"One of the real advantages of this multiscale and tissue science is that it will more fully define what the cancers are at different interfaces," Gray added. "For the first time in history, we have the measurement technology to do this in a way to understand the cells and tissues across time and space domains."
Provided by Pacific Northwest National Laboratory
- Berkeley Lab scientist co-leads breast cancer 'dream team' May 27, 2009 | not rated yet | 0
- Estrogen receptor status of HER2+ breast cancer correlates with response to anti-HER therapies May 06, 2010 | not rated yet | 0
- Herceptin targets breast cancer stem cells Jul 09, 2008 | not rated yet | 0
- Scientists show protein accelerates breast cancer progression in animal models Jun 20, 2007 | not rated yet | 0
- Therapy may block expansion of breast cancer cells Nov 05, 2008 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Why is zone 1 in liver more prone to ischemic injury?
May 23, 2013 Hi, Is it because around central vein, there is only deoxygenated blood from the vein where as in the periphery there is hepatic artery. Also why...
How can there be villous adenoma in colon, if there are no villi there
May 22, 2013 As title suggest. Thanks :smile:
How can there be a term called "intestinal metaplasia" of stomach
May 21, 2013 Hello everyone, Ok Stomach's normal epithelium is simple columnar, now in intestinal type of adenocarcinoma of stomach it undergoes "intestinal...
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013 From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
May 17, 2013 I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
- More from Physics Forums - Medical Sciences
More news stories
In recent years, microRNAs (miRNAs) and other non-coding RNAs are small molecules that help control the expression of specific proteins. In recent years they have emerged as disease biomarkers. miRNA profiles have been used ...
Cancer 12 hours ago | not rated yet | 0
Cancer cells spread and grow by avoiding detection and destruction by the immune system. Stimulation of the immune system can help to eliminate cancer cells; however, there are many factors that cause the immune system to ...
Cancer 12 hours ago | not rated yet | 0
Researchers from London's Kingston University have begun a two-year study which could help prolong the lives of people with colorectal tumours.
Cancer 15 hours ago | 5 / 5 (1) | 0
Transformative research from Western University has identified new hormones in the body which may suppress breast cancer and stimulate the regression of breast tumors.
Cancer 16 hours ago | 5 / 5 (1) | 0
(Medical Xpress)—Curtin University researchers have found evidence that targeting specific cells in the body can reverse the effects of cancer on the immune system.
Cancer 16 hours ago | 5 / 5 (3) | 0
(Medical Xpress)—A new study by researchers in the US has shown that an ancient virus can be modified to help in the fight against the simian immunodeficiency virus SIV, which is the equivalent in monkeys ...
15 hours ago | 5 / 5 (3) | 0 |
Two mutations central to the development of infantile myofibromatosis (IM)—a disorder characterized by multiple tumors involving the skin, bone, and soft tissue—may provide new therapeutic targets, according to researchers ...
10 hours ago | 3 / 5 (2) | 0 |
Women at a particular stage in their monthly menstrual cycle may be more vulnerable to some of the psychological side-effects associated with stressful experiences, according to a study from UCL.
12 hours ago | 3.7 / 5 (3) | 0 |
Biological processes are generally based on events at the molecular and cellular level. To understand what happens in the course of infections, diseases or normal bodily functions, scientists would need to ...
13 hours ago | 5 / 5 (4) | 0 |
How can healthy people who hear voices help schizophrenics? Finding the answer for this is at the centre of research conducted at the University of Bergen.
15 hours ago | 4 / 5 (2) | 2
Talking on a hands-free device while behind the wheel can lead to a sharp increase in errors that could imperil other drivers on the road, according to new research from the University of Alberta.
9 hours ago | not rated yet | 0